November 2021 - Biologics by McKesson

Aplastic Anemia/MDS International Foundation Q&A

Nov 19, 2021 | Patient Advocacy

What is the Aplastic Anemia and MDS International Foundation? The Aplastic Anemia and MDS International Foundation (AAMDSIF) is dedicated to assisting and supporting people who have bone marrow disorders, including aplastic anemia, myelodysplastic syndrome and...

EXKIVITY (mobocertinib), First and Only FDA Approved Oral Treatment of EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer, Available at Biologics by McKesson

Nov 3, 2021 | Press Release

CARY, N.C., NOVEMBER 3, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Takeda Pharmaceutical Limited Company as a specialty pharmacy provider for EXKIVITY™ (mobocertinib) for the...

Aplastic Anemia/MDS International Foundation Q&A

EXKIVITY (mobocertinib), First and Only FDA Approved Oral Treatment of EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer, Available at Biologics by McKesson

Recent Posts

Archives